CFSAN program priorities
This article was originally published in The Tan Sheet
Executive Summary
FDA requests public comment on the center's year 2000 program priorities in a Sept. 1 Federal Register. The deadline for comments is Sept. 30. FDA intends to make the new workplan public in January. The center continues work on its 1999 strategic plan "A-List" priorities, including resolution of issues involving ephedra-containing supplements, prompt review of new dietary ingredients, implementation of the authoritative statement provision of the FDA Modernization Act, development of an overall strategy on dietary supplements and issues involving third-party literature (1"The Tan Sheet" Feb. 1, p. 9). In July, CFSAN added to its "A List" development of a response strategy to the federal appeals court decision in Pearson v. Shalala (2"The Tan Sheet" July 12, In Brief)
You may also be interested in...
CFSAN program priorities
Pearson v. Shalala agency response strategy added to the center's "A-List" of priorities to be tackled in 1999, center Director Joseph Levitt says in an attachment to a July 2 "Dear Colleague" letter. Under the Jan. 15 federal appeals court decision, the agency must clarify the "significant scientific agreement" standard for health claims and reconsider whether four specific supplement health claims previously denied by FDA should be allowed with appropriate labeling disclaimers. FDA declined to appeal the decision to the Supreme Court (1"The Tan Sheet" July 5, In Brief)
CFSAN Strategic Plan Focuses On Ephedra, Nutrient Content/Health Claims
FDA's Center for Food Safety & Applied Nutrition strategic plan, entitled "1999 CFSAN Program Priorities," addresses issues surrounding the dietary supplement ephedra as well as publishing a proposed rule covering nutrient content/health claims based on authoritative statements. The plan was discussed at a press briefing Jan. 26.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC